Get started
Author

Yasushi Ide

Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease
2006 · Yuichiro Eguchi, Takahisa Eguchi, et al. · Journal of Gastroenterology · 287
Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in J apanese patients ( LEAN ‐ J )
2014 · Yuichiro Eguchi, Yoichiro Kitajima, et al. · Hepatology Research · 187
Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment
2015 · Saori Kamachi, Toshihiko Mizuta, et al. · Hepatology Research · 97
Menatetrenone, a Vitamin K2 Analogue, Inhibits Hepatocellular Carcinoma Cell Growth by Suppressing Cyclin D1 Expression through Inhibition of Nuclear Factor κB Activation
2007 · Iwata Ozaki, Hao Zhang, et al. · Clinical Cancer Research · 79
Effect of Intramuscular Adipose Tissue Content on Prognosis in Patients Undergoing Hepatocellular Carcinoma Resection
2015 · Masaki Kaibori, Morihiko Ishizaki, et al. · Journal of Gastrointestinal Surgery · 64
Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group
2018 · Toshie Mashiba, Kouji Joko, et al. · PLoS ONE · 59
PDF
Effects of home‐based exercise and branched‐chain amino acid supplementation on aerobic capacity and glycemic control in patients with cirrhosis
2016 · Yuichiro Nishida, Yasushi Ide, et al. · Hepatology Research · 56
PDF
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
2021 · Kaoru Tsuchiya, Masayuki Kurosaki, et al. · Cancers · 54
PDF
Waist circumference correlates with hepatic fat accumulation in male Japanese patients with non‐alcoholic fatty liver disease, but not in females
2008 · Eriko Ishibashi, Yuichiro Eguchi, et al. · Journal of Gastroenterology and Hepatology · 44
PDF
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
2016 · Jun Itakura, Masayuki Kurosaki, et al. · PLoS ONE · 40
Real‐world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group
2018 · Takehiro Akahane, Masayuki Kurosaki, et al. · Hepatology Research · 33
Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group
2021 · Toshifumi Tada, Masayuki Kurosaki, et al. · Journal of Medical Virology · 30
Real‐world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group
2019 · Toshie Mashiba, Kouji Joko, et al. · Hepatology Research · 24
PDF
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study
2021 · Taiga Otsuka, Tsuyoshi Shirakawa, et al. · International Journal of Clinical Oncology · 23
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
2023 · Tsuyoshi Shirakawa, Akitaka Makiyama, et al. · Scientific Reports · 22
PDF
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)
2021 · Futa Koga, Yasunori Kawaguchi, et al. · Journal of Geriatric Oncology · 21
The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey
2014 · Takumi Kawaguchi, Motoyuki Kohjima, et al. · Journal of Gastroenterology · 19
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
2023 · Masaru Fukahori, Yoshinobu Okabe, et al. · Scientific Reports · 18
PDF
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)
2022 · Taro Shibuki, Toshihiko Mizuta, et al. · BMC Cancer · 17
PDF
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
2023 · YASUSHI IDE, TAIGA OTSUKA, et al. · Anticancer Research · 15
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study)
2021 · Shiho Arima, Machiko Kawahira, et al. · Pancreas · 12
Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis
2018 · Hideki Fujii, Hiroyuki Kimura, et al. · Hepatology Research · 12
Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case
2014 · Takashi Okumura, Jun Nakamura, et al. · World Journal of Surgical Oncology · 11
PDF
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel
2024 · Taro Shibuki, Taiga Otsuka, et al. · Scientific Reports · 9
PDF
A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study
2019 · J. Nakazawa, T. Otsuka, et al. · Annals of Oncology · 9
Works count: 63
Citation count: 1,302
H-index: 18
I10-index: 23
Year
Topic
Type